PD-1 knockout EBV-CTL (Nanjing Medical University)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePD-1 knockout EBV-CTL (Nanjing Medical University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Cell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Virus-specific T Cell therapy +[4] 
Mechanisms of ActionT lymphocyte replacementsProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsNasopharyngeal NeoplasmsStomach NeoplasmsLymphoma, Large B-Cell, Diffuse +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNanjing Medical University
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Medical University
Inactive CompaniesN/A
Active IndicationsNasopharyngeal NeoplasmsStomach NeoplasmsLymphoma, Large B-Cell, Diffuse +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A